Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206263681> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4206263681 endingPage "S91" @default.
- W4206263681 startingPage "S91" @default.
- W4206263681 abstract "Sickle cell disease is a burdensome disease with limited treatment options. Given how inconclusive the evidence is for some of the newer agents, clinicians seem to only have hydroxyurea and crizanlizumab as treatment options for preventing vaso-occlusive events in patients with SCD. To estimate the cost-utility of preventing vaso-occlusive events in patients with sickle cell disease with crizanlizumab since the age 16 in the United States. We used a Markov model with two health states (sickle cell disease at baseline and dead) and two transition states (vaso-occlusive events and vaso-occlusive events requiring hospitalization). Utilities were presented as Quality-adjusted Life Years. A societal perspective was taken when calculating incremental cost-utility. Costs were elicited via macro-costing with model inputs being adjusted to 2020 US Dollars. Using crizanlizumab to prevent vaso-occlusive events in patients with SCD resulted in an incremental 2.527 quality-adjusted life-years with $725,917 in added costs (ICER = $287,263/QALY) over a lifetime period. Effectiveness of crizanlizumab and its drug price were the parameters to which the ICER was most sensitive. To achieve a willingness to pay threshold of $150,000/QALY, crizanlizumab costs could not amount to more than $58,000 per year to be considered cost-effective. Crizanlizumab is not cost-effective in this model in preventing vaso-occlusive events in patients with SCD. Drug price and relative effectiveness of crizanlizumab when compared to hydroxyurea were key drivers of this cost-effectiveness analysis." @default.
- W4206263681 created "2022-01-26" @default.
- W4206263681 creator A5025169835 @default.
- W4206263681 creator A5032976392 @default.
- W4206263681 creator A5084033956 @default.
- W4206263681 date "2022-01-01" @default.
- W4206263681 modified "2023-09-27" @default.
- W4206263681 title "POSB156 Cost-Utility Analysis of Crizanlizumab and Hydroxyurea in Preventing Vaso-Occlusive Events in Patients with Sickle-Cell Disease: A Lifetime Model from a Payer's and Societal Perspectives" @default.
- W4206263681 doi "https://doi.org/10.1016/j.jval.2021.11.429" @default.
- W4206263681 hasPublicationYear "2022" @default.
- W4206263681 type Work @default.
- W4206263681 citedByCount "0" @default.
- W4206263681 crossrefType "journal-article" @default.
- W4206263681 hasAuthorship W4206263681A5025169835 @default.
- W4206263681 hasAuthorship W4206263681A5032976392 @default.
- W4206263681 hasAuthorship W4206263681A5084033956 @default.
- W4206263681 hasBestOaLocation W42062636811 @default.
- W4206263681 hasConcept C112930515 @default.
- W4206263681 hasConcept C126322002 @default.
- W4206263681 hasConcept C144133560 @default.
- W4206263681 hasConcept C162853370 @default.
- W4206263681 hasConcept C164624739 @default.
- W4206263681 hasConcept C177713679 @default.
- W4206263681 hasConcept C2778620579 @default.
- W4206263681 hasConcept C2779134260 @default.
- W4206263681 hasConcept C2780075939 @default.
- W4206263681 hasConcept C2780441568 @default.
- W4206263681 hasConcept C3019080777 @default.
- W4206263681 hasConcept C64332521 @default.
- W4206263681 hasConcept C71924100 @default.
- W4206263681 hasConceptScore W4206263681C112930515 @default.
- W4206263681 hasConceptScore W4206263681C126322002 @default.
- W4206263681 hasConceptScore W4206263681C144133560 @default.
- W4206263681 hasConceptScore W4206263681C162853370 @default.
- W4206263681 hasConceptScore W4206263681C164624739 @default.
- W4206263681 hasConceptScore W4206263681C177713679 @default.
- W4206263681 hasConceptScore W4206263681C2778620579 @default.
- W4206263681 hasConceptScore W4206263681C2779134260 @default.
- W4206263681 hasConceptScore W4206263681C2780075939 @default.
- W4206263681 hasConceptScore W4206263681C2780441568 @default.
- W4206263681 hasConceptScore W4206263681C3019080777 @default.
- W4206263681 hasConceptScore W4206263681C64332521 @default.
- W4206263681 hasConceptScore W4206263681C71924100 @default.
- W4206263681 hasIssue "1" @default.
- W4206263681 hasLocation W42062636811 @default.
- W4206263681 hasOpenAccess W4206263681 @default.
- W4206263681 hasPrimaryLocation W42062636811 @default.
- W4206263681 hasRelatedWork W1841572063 @default.
- W4206263681 hasRelatedWork W2012275752 @default.
- W4206263681 hasRelatedWork W2103856899 @default.
- W4206263681 hasRelatedWork W2125060934 @default.
- W4206263681 hasRelatedWork W2137780073 @default.
- W4206263681 hasRelatedWork W2146826683 @default.
- W4206263681 hasRelatedWork W2150481879 @default.
- W4206263681 hasRelatedWork W2769145536 @default.
- W4206263681 hasRelatedWork W3027226889 @default.
- W4206263681 hasRelatedWork W4322706390 @default.
- W4206263681 hasVolume "25" @default.
- W4206263681 isParatext "false" @default.
- W4206263681 isRetracted "false" @default.
- W4206263681 workType "article" @default.